Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Medical Microbiology and Immunology

Volumn 204, Issue 1, 2015, Pages 87-94

  Koh, Sarene ^a   Bertoletti, Antonio ^a,b  

^a AGENCY FOR SCIENCE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Hepatitis B virus; T cells; Therapeutic vaccination

Indexed keywords

ALPHA INTERFERON; B LYMPHOCYTE ANTIBODY; HEPATITIS B VACCINE; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; INFECTION CONTROL; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PERSISTENT VIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEROCONVERSION; VACCINE FAILURE; VIRAL CLEARANCE; VIRAL GENE DELIVERY SYSTEM; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; HEPATITIS B, CHRONIC; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; T-LYMPHOCYTES;

EID: 84925482318     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-014-0377-7     Document Type: Review

References (87)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST (2012) Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30:2212–2219. doi:10.1016/j.vaccine.2011.12.116
2. Ni Y-H, Huang L-M, Chang M-H et al (2007) Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 132:1287–1293. doi:10.1053/j.gastro.2007.02.055
3. Chang M-H, You S-L, Chen C-J et al (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101:1348–1355. doi:10.1093/jnci/djp288
4. Cooksley WGE, Piratvisuth T, Lee S-D et al (2003) Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10:298–305
5. Lau GKK, Piratvisuth T, Luo KX et al (2005) Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352:2682–2695. doi:10.1056/NEJMoa043470
6. Dienstag JL (2008) Hepatitis B virus infection. N Engl J Med 359:1486–1500. doi:10.1056/NEJMra0801644
7. Bertoletti A, Ferrari C, Fiaccadori F et al (1991) HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 88:10445–10449
8. Maini MK, Boni C, Ogg GS et al (1999) Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 117:1386–1396
9. Penna A, Chisari FV, Bertoletti A et al (1991) Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 174:1565–1570
10. Penna A, Del Prete G, Cavalli A et al (1997) Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 25:1022–1027. doi:10.1002/hep.510250438
11. Rehermann BB, Fowler P, Sidney J et al (1995) The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181:1047–1058
12. Wieland S, Thimme R, Purcell RH, Chisari FV (2004) Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101:6669–6674. doi:10.1073/pnas.0401771101
13. Stacey AR, Norris PJ, Qin L et al (2009) Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 83:3719–3733. doi:10.1128/JVI.01844-08
14. Dunn C, Peppa D, Khanna P et al (2009) Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137:1289–1300. doi:10.1053/j.gastro.2009.06.054
15. Tan AT, Koh S, Goh V, Bertoletti A (2008) Understanding the immunopathogenesis of chronic hepatitis B virus: an Asian prospective. J Gastroenterol Hepatol 23:833–843. doi:10.1111/j.1440-1746.2008.05385.x
16. Bertoletti A, Ferrari C (2012) Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61:1754–1764. doi:10.1136/gutjnl-2011-301073
17. Chisari FV (1997) Cytotoxic T cells and viral hepatitis. J Clin Invest 99:1472–1477. doi:10.1172/JCI119308
18. Alberti A, Diana S, Sculard GH et al (1978) Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. Br Med J 2:1056–1058
19. Asabe S, Wieland SF, Chattopadhyay PK et al (2009) The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 83:9652–9662. doi:10.1128/JVI.00867-09
20. Publicover J, Gaggar A, Nishimura S et al (2013) Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest 123:3728–3739. doi:10.1172/JCI68182.3728
21. Kamatani Y, Wattanapokayakit S, Ochi H et al (2009) A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 41:591–595. doi:10.1038/ng.348
22. Bertoletti A, Gehring A (2007) Immune response and tolerance during chronic hepatitis B virus infection. Hepatol Res 37(Suppl 3):S331–S338. doi:10.1111/j.1872-034X.2007.00221.x
23. Seeger C, Mason WS (2000) Hepatitis B virus biology. Microbiol Mol Biol Rev 64:51–68. doi:10.1128/MMBR.64.1.51-68.2000.Updated
24. Van der Molen RG, Sprengers D, Binda RS et al (2004) Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40:738–746. doi:10.1002/hep.20366
25. Op den Brouw ML, Binda RS, van Roosmalen MH et al (2009) Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 126:280–289. doi:10.1111/j.1365-2567.2008.02896.x
26. Woltman AM, Op den Brouw ML, Biesta PJ et al (2011) Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE 6:e15324. doi:10.1371/journal.pone.0015324
27. Xu Y, Hu Y, Shi B et al (2009) HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 46:2640–2646. doi:10.1016/j.molimm.2009.04.031
28. Shi B, Ren G, Hu Y et al (2012) HBsAg inhibits IFN-α production in plasmacytoid dendritic cells through TNF-α and IL-10 induction in monocytes. PLoS ONE 7:e44900. doi:10.1371/journal.pone.0044900
29. Beckebaum S, Cicinnati VR, Zhang X et al (2003) Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology 109:487–495
30. Wu J, Meng Z, Jiang M et al (2009) Hepatitis B virus suppresses Toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49:1132–1140. doi:10.1002/hep.22773
31. Martinet J, Dufeu-Duchesne T, Bruder Costa J et al (2012) Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology 143:1586–1596. doi:10.1053/j.gastro.2012.08.046
32. Andrade BB, Santos CJN, Camargo LM et al (2011) Hepatitis B infection is associated with asymptomatic malaria in the Brazilian Amazon. PLoS ONE 6:e19841. doi:10.1371/journal.pone.0019841
33. Oakley MS, Sahu BR, Lotspeich-Cole L et al (2013) The transcription factor T-bet regulates parasitemia and promotes pathogenesis during Plasmodium berghei ANKA murine malaria. J Immunol 191:4699–4708. doi:10.4049/jimmunol.1300396
34. Rodrick ML, Moss NM, Grbic JT et al (1992) Effects of in vivo endotoxin infusions on in vitro cellular immune responses in humans. J Clin Immunol 12:440–450
35. Granowitz EV, Porat R, Mier JW et al (1993) Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol 151:1637–1645
36. Das A, Ellis G, Pallant C et al (2012) IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol 189:3925–3935. doi:10.4049/jimmunol.1103139
37. Sandalova E, Laccabue D, Boni C et al (2012) Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology 143:78–87. doi:10.1053/j.gastro.2012.03.041
38. Das A, Hoare M, Davies N et al (2008) Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 205:2111–2124. doi:10.1084/jem.20072076
39. Gehring AJ, Haniffa M, Kennedy PT et al (2013) Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest 123:3766–3776. doi:10.1172/JCI66043DS1
40. Boni C, Fisicaro P, Valdatta C et al (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81:4215–4225. doi:10.1128/JVI.02844-06
41. Webster GJM, Reignat S, Brown D et al (2004) Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78:5707–5719. doi:10.1128/JVI.78.11.5707
42. Isogawa M, Furuichi Y, Chisari FV (2005) Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. Immunity 23:53–63. doi:10.1016/j.immuni.2005.05.005
43. Isogawa M, Kakimi K, Kamamoto H et al (2005) Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology 333:293–300. doi:10.1016/j.virol.2005.01.004
44. Fisicaro P, Valdatta C, Massari M et al (2012) Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 143:1576–1585. doi:10.1053/j.gastro.2012.08.041
45. Wooddell CI, Rozema DB, Hossbach M et al (2013) Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 21:973–985. doi:10.1038/mt.2013.31
46. Ilan Y, Nagler A, Adler R et al (1993) Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 104:1818–1821
47. Lau GKK, Suri D, Liang R et al (2002) Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122:614–624. doi:10.1053/gast.2002.31887
48. Lau GK, Lok AS, Liang RH et al (1997) Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 25:1497–1501. doi:10.1002/hep.510250631
49. Ferrari C, Penna A, Bertoletti A et al (1990) Cellular immune response to hepatitis b virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 145:3442–3449
50. Jung MC, Spengler U, Schraut W et al (1991) Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol 13:310–317
51. Loggi E, Bihl F, Chisholm JV et al (2009) Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J Hepatol 50:625–630. doi:10.1016/j.jhep.2008.08.026
52. Couillin I, Pol S, Mancini M et al (1999) Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 180:15–26. doi:10.1086/314828
53. Pol S, Nalpas B, Driss F et al (2001) Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34:917–921
54. Yalcin K, Acar M, Degertekin H (2003) Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection 31:221–225
55. Dahmen A, Herzog-hauff S, Bocher WO et al (2002) Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 460:452–460. doi:10.1002/jmv.2165
56. Vandepapelière P, Lau GKK, Leroux-Roels G et al (2007) Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25:8585–8597. doi:10.1016/j.vaccine.2007.09.072
57. Rahman F, Dahmen A, Herzog-Hauff S et al (2000) Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 31:521–527. doi:10.1002/hep.510310237
58. Jung M-C, Grüner N, Zachoval R et al (2002) Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 20:3598–3612. doi:10.1016/S0264-410X(02)00309-2
59. Heathcote J, McHutchison J, Lee S et al (1999) A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 30:531–536
60. Mancini-Bourgine M, Fontaine H, Scott-Algara D et al (2004) Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40:874–882. doi:10.1002/hep.20408
61. Mancini-Bourgine M, Fontaine H, Bréchot C et al (2006) Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24:4482–4489. doi:10.1016/j.vaccine.2005.08.013
62. Yao X, Zheng B, Zhou J et al (2007) Therapeutic effect of hepatitis B surface antigen–antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25:1771–1779. doi:10.1016/j.vaccine.2006.11.019
63. Xu D-Z, Zhao K, Guo L-M et al (2008) A randomized controlled phase IIb trial of antigen–antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 3:e2565. doi:10.1371/journal.pone.0002565
64. Xu D-Z, Wang X-Y, Shen X-L et al (2013) Results of a phase III clinical trial with an HBsAg–HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 59:450–456. doi:10.1016/j.jhep.2013.05.003
65. Sallberg M, Hughes J, Javadian A et al (1998) Genetic Immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther 9:1719–1729
66. Depla E, Van der Aa A, Livingston BD et al (2008) Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol 82:435–450. doi:10.1128/JVI.01505-07
67. Kosinska AD, Zhang E, Johrden L et al (2013) Combination of DNA prime–adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog 9:e1003391. doi:10.1371/journal.ppat.1003391
68. Tan AT, Hoang LT, Chin D et al (2014) Reduction of HBV replication prolongs the early immunological response to IFNα therapy. J Hepatol 60:54–61. doi:10.1016/j.jhep.2013.08.020
69. Boni C, Penna A, Bertoletti A et al (2003) Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39:595–605. doi:10.1016/S0168-8278(03)00292-7
70. Huang L-R, Wohlleber D, Reisinger F et al (2013) Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 14:574–583. doi:10.1038/ni.2573
71. Isogawa M, Chung J, Murata Y et al (2013) CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathog 9:e1003490. doi:10.1371/journal.ppat.1003490
72. Guptan RC, Thakur V, Kazim SN, Sarin SK (2002) Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients. J Gastroenterol Hepatol 17:765–771
73. Martin J, Bosch O, Moraleda G et al (1993) Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B. Hepatology 18:775–780
74. Van Thiel DH, Friedlander L, Kania RJ et al (1997) A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy. J Viral Hepat 4(Suppl 1):101–106
75. Fisicaro P, Valdatta C, Massari M et al (2010) Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138:682–693. doi:10.1053/j.gastro.2009.09.052
76. Nebbia G, Peppa D, Schurich A et al (2012) Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS ONE 7:e47648. doi:10.1371/journal.pone.0047648
77. Raziorrouh B, Schraut W, Gerlach T et al (2010) The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 52:1934–1947. doi:10.1002/hep.23936
78. Armand P, Nagler A, Weller EA et al (2013) Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 31:4199–4206
79. Liu J, Zhang E, Ma Z et al (2014) Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 10:e1003856. doi:10.1371/journal.ppat.1003856
80. Gehring AJ, Xue S-A, Ho ZZ et al (2011) Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 55:103–110. doi:10.1016/j.jhep.2010.10.025
81. Koh S, Shimasaki N, Suwanarusk R et al (2013) A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids 2:e114. doi:10.1038/mtna.2013.43
82. Krebs K, Böttinger N, Huang L-R et al (2013) T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145:456–465. doi:10.1053/j.gastro.2013.04.047
83. Ji C, Sastry KSR, Tiefenthaler G et al (2012) Targeted delivery of interferon- a to hepatitis B virus- infected cells using T-cell receptor-like antibodies. Hepatology 56:2027–2038. doi:10.1002/hep.25875
84. Micco L, Peppa D, Loggi E et al (2013) Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 58:225–233. doi:10.1016/j.jhep.2012.09.029
85. Lanford RE, Guerra B, Chavez D et al (2013) GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144:1508–1517. doi:10.1053/j.gastro.2013.02.003
86. Tu Z, Bozorgzadeh A, Pierce RH et al (2008) TLR-dependent cross talk between human Kupffer cells and NK cells. J Exp Med 205:233–244. doi:10.1084/jem.20072195
87. Schurich A, Pallett LJ, Lubowiecki M et al (2013) The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 9:e1003208. doi:10.1371/journal.ppat.1003208